Assessing Alnylam Pharmaceuticals (ALNY) Valuation After Mixed Share Performance And Strong AMVUTTRA Uptake

Simply Wall St.05-23 22:28

AdvertisementWhat recent price moves tell you about Alnylam Pharmaceuticals (ALNY) Alnylam Pharmaceuticals (ALNY) has drawn investor attention after a period of mixed share performance, with the stock...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2637207943?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-05-23 22:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637207943","market":"us","top_or_hot":-1,"title":"Assessing Alnylam Pharmaceuticals (ALNY) Valuation After Mixed Share Performance And Strong AMVUTTRA Uptake","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhat recent price moves tell you about Alnylam Pharmaceuticals (ALNY) Alnylam Pharmaceuticals (ALNY) has drawn investor attention after a period of mixed share performance, with the stock...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/assessing-alnylam-pharmaceuticals-alny-valuation-after-mixed\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Alnylam Pharmaceuticals (ALNY) Valuation After Mixed Share Performance And Strong AMVUTTRA Uptake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Alnylam Pharmaceuticals (ALNY) Valuation After Mixed Share Performance And Strong AMVUTTRA Uptake\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-23 22:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/assessing-alnylam-pharmaceuticals-alny-valuation-after-mixed><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhat recent price moves tell you about Alnylam Pharmaceuticals (ALNY) Alnylam Pharmaceuticals (ALNY) has drawn investor attention after a period of mixed share performance, with the stock...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/assessing-alnylam-pharmaceuticals-alny-valuation-after-mixed\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/assessing-alnylam-pharmaceuticals-alny-valuation-after-mixed","article_id":"2637207943","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/assessing-alnylam-pharmaceuticals-alny-valuation-after-mixed","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2637207943","pubTimestamp":1779546485,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"What recent price moves tell you about Alnylam Pharmaceuticals (ALNY)\nAlnylam Pharmaceuticals (ALNY) has drawn investor attention after a period of mixed share performance, with the stock down over the past month and past 3 months but slightly higher over the past year.\nSee our latest analysis for Alnylam Pharmaceuticals.\nAt a share price of US$297.45, Alnylam’s short term share price return has been weak, with the stock down year to date. Longer term total shareholder returns over 3 and 5...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","ALNY":"阿尔尼拉姆制药公司","BK4548":"巴美列捷福持仓"},"translate_title":"在股票表现好坏参半和AMVUTTRA强劲吸收后评估Alnylam Pharmaceuticals(ALNY)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":1.5},"content_text":"AdvertisementWhat recent price moves tell you about Alnylam Pharmaceuticals (ALNY) Alnylam Pharmaceuticals (ALNY) has drawn investor attention after a period of mixed share performance, with the stock down over the past month and past 3 months but slightly higher over the past year. See our latest analysis for Alnylam Pharmaceuticals. At a share price of US$297.45, Alnylam’s short term share price return has been weak, with the stock down year to date. Longer term total shareholder returns over 3 and 5 years have been positive, hinting at shifting views on its growth and risk profile. If you are weighing Alnylam against other opportunities in the sector, this can be a good moment to see how specialist healthcare AI stocks are trading through our 34 healthcare AI stocks So with Alnylam trading at US$297.45, a value score of 2 and a market cap around US$40.1b, are you looking at an underappreciated RNAi leader, or has the market already priced in its future growth potential? Most Popular Narrative: 40% Undervalued With Alnylam last closing at $297.45 against a narrative fair value of about $491.92, the most followed storyline sees a sizeable gap between price and projected potential, built on ambitious growth and margin assumptions.  The rapid and robust uptake of AMVUTTRA for ATTR-CM in its first full quarter post-approval, combined with near-universal first-line payer access and minimal patient out-of-pocket costs, indicates a much larger addressable market for Alnylam's RNAi therapies as diagnostics and disease awareness improve, supporting sustained double-digit revenue growth.  Read the complete narrative. Curious what kind of revenue curve and profit margin uplift would need to hold for that fair value to stack up? The narrative leans on faster top line expansion, widening profitability, and a richer future earnings multiple than the broader US Biotechs industry. Want to see exactly how those moving parts are combined into that higher valuation story? Result: Fair Value of $491.92 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this story could change fast if AMVUTTRA pricing or reimbursement comes under pressure, or if heavy R&D and SG&A spending outpaces future revenue gains. Find out about the key risks to this Alnylam Pharmaceuticals narrative. Another Way To Look At The Valuation On simple P/E terms, Alnylam trades at 73.8x, which is much richer than the US Biotechs industry at 16.1x, peers at 30.1x, and even its own fair ratio of 29.7x. That gap points to meaningful valuation risk if sentiment or growth expectations cool. How comfortable are you paying that kind of premium? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:ALNY P/E Ratio as at May 2026Next Steps With such mixed signals across price, valuation and growth narratives, now is the moment to review the underlying data yourself and consider acting before sentiment shifts. To help you weigh both the upside case and the concerns in one place, check out the 3 key rewards and 1 important warning sign Looking for more investment ideas? If you stop with just one stock, you risk missing other compelling setups that could fit your goals even better, so widen your search before you commit.  Target potential bargains by scanning companies that appear mispriced on quality and fundamentals through the 49 high quality undervalued stocks. Strengthen your core holdings by focusing on companies with healthier finances using the solid balance sheet and fundamentals stocks screener (46 results). Get ahead of the crowd by filtering for future standouts with the screener containing 21 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2637207943","isCrawlerRequest":true}